In addition to determining the in vivo oncogenicity of specific Kras variants, our barcode-sequencing approach allowed us to identify contiguous tumor clones from multi-region sequencing of PDAC masses (Fig. 7c and Supplementary Fig. 13b). This evidence concerns the gene KRAS and neoplasm.